SLC14A2

Across TCGA pan-cancer cohorts, SLC14A2 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SLC14A2 data layer compared with 26 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher SLC14A2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SLC14A2 expression acts as an unfavorable survival marker, although some lineages such as SKCM and OV show a favorable association.

KIRC, SKCM, and OV are the cancer types where SLC14A2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	DFS	Median	All	0.123	0.796	<.001	30	view →
SKCM	OS	Median	II,III,IV	0.918	0.708	.007	12	view →
OV	DFS	Median	All	1.000	0.156	.037	8	view →
KIRP	DFS	Median	All	0.277	0.867	.004	6	view →
GBM	OS	Median	All	0.134	0.421	.004	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SLC14A2–KIRC (DFS)

Open the KIRC breakdown →